Arrowhead Q1 revenue $264M; REDEMPLO launched; $930M financing closed

ARROWHEAD PHARMACEUTICALS, INC.

2026-Q1 EPS reported $0.22 revenue$264,033,000

Revenue $264M (vs $2.5M YoY); net income $30.8M ($0.22 diluted EPS) vs loss $173M.
REDEMPLO FDA-approved for FCS; over 100 prescriptions received since US launch.
Closed $930M public offerings: $0% convertible notes due 2032 + stock at $64.50/sh.
Novartis collaboration for ARO-SNCA: $200M upfront, up to $2B milestones, royalties.
Obesity candidate ARO-INHBE + tirzepatide achieved -9.4% weight loss at week 16.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.